Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trialModupe Idowu, Wally R. Smith, Lucas Otieno et al.|The Lancet Haematology|2024Cited by 25
Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphomaRebecca Elstrom, Richard R. Furman, John P. Leonard et al.|Leukemia & lymphoma/Leukemia and lymphoma|2012Cited by 22
FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphomaSarah C. Rutherford, John P. Leonard, Biree Andemariam et al.|Leukemia & lymphoma/Leukemia and lymphoma|2008Cited by 19